Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications.
Cohen
Margo P
MP
University City Science Center, Philadelphia, Pennsylvania, USA. drmpcohen@aol.com
Ziyadeh
Fuad N
FN
Chen
Sheldon
S
D050197:Atherosclerosis / Q000097:blood* / Q000209:etiology; D048909:Diabetes Complications / Q000097:blood* / Q000473:pathology; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D012709:Serum Albumin / Q000378:metabolism*; D000093423:Glycated Serum Albumin; D000093844:Glycated Proteins
D017127:Glycation End Products, Advanced; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D012709:Serum Albumin; D000093423:Glycated Serum Albumin; C051724:glycated lipoproteins, HDL; D000093844:Glycated Proteins; C031797:glycated lipoproteins, LDL